Is Tri‑Lo‑Marzia (ethinyl estradiol/norgestimate) safe for a woman with risk factors for venous thromboembolism, and what is her risk of pulmonary embolism?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Tri-Lo-Marzia is contraindicated in women with risk factors for venous thromboembolism and carries a 2-6 fold increased risk of pulmonary embolism compared to non-users.

Absolute Contraindications for Tri-Lo-Marzia

Tri-Lo-Marzia (norgestimate/ethinyl estradiol) must not be prescribed if the patient has any of the following 1:

  • Personal history of deep vein thrombosis or pulmonary embolism (past or present)
  • Inherited or acquired thrombophilia (Factor V Leiden, prothrombin mutation, protein C/S deficiency, antithrombin deficiency)
  • Age >35 years who smokes
  • Uncontrolled hypertension
  • Diabetes with vascular complications
  • Migraine with aura (any age) or any migraine if age >35
  • Prolonged immobilization or major surgery planned

Quantifying the PE Risk

The baseline risk of VTE in young women not using hormonal contraception is 0.3-0.5 per 10,000 woman-years 2. Combined oral contraceptives increase this risk 3-6 fold to approximately 3-9 per 10,000 woman-years 3.

Norgestimate specifically (the progestin in Tri-Lo-Marzia) carries a lower VTE risk compared to third-generation progestins. Studies show norgestimate has a VTE risk similar to levonorgestrel (the lowest-risk progestin), with an incidence of approximately 30.6 per 100,000 woman-years 4. This is significantly lower than desogestrel (53.5 per 100,000) or drospirenone-containing pills 4, 5.

Risk Amplification with Additional Factors

The thrombogenic effect multiplies dramatically when combined with other risk factors 6:

  • Inherited thrombophilia: Risk multiplied by 5-16 fold on top of the COC baseline risk 6
  • Age >40 years: Significantly increased risk 6
  • Obesity: Additive risk 6
  • First year of use: Highest risk period 6
  • Smoking: Independent PE risk factor that compounds COC risk 2

Clinical Decision Algorithm

If the patient has ANY of the following, do NOT prescribe Tri-Lo-Marzia:

  1. Personal history of VTE (DVT/PE)
  2. Known thrombophilia
  3. First-degree relative with VTE before age 60
  4. Age >35 + smoking
  5. Recent major surgery or prolonged immobilization planned

Alternative contraceptive options for women with VTE risk factors 6:

  • First-line: Copper IUD (no hormones, no VTE risk)
  • Second-line: Progestin-only methods
    • Levonorgestrel IUD (no increased VTE risk) 6
    • Progestin-only pills (desogestrel 75mcg, norethisterone) - no significant VTE increase 6
    • Etonogestrel implant (no VTE risk) 7

Important Caveats

Screening for thrombophilia is NOT routinely recommended before prescribing COCs unless there is a first-degree family history of VTE before age 60 6. If screening is indicated, test for: PT, aPTT, antithrombin, protein C, protein S, Factor V Leiden, and prothrombin 20210A mutation 6.

Superficial venous thrombosis alone does not contraindicate hormonal contraception 6.

The 2019 ESC guidelines emphasize that oral contraceptives are the most frequent VTE risk factor in women of reproductive age 3, and third-generation progestins (desogestrel, gestodene) carry 50-80% higher VTE risk than levonorgestrel 8. Norgestimate, while technically "third-generation," behaves more like second-generation levonorgestrel in terms of VTE risk 4, 9, 10.

For context: Pregnancy itself carries a VTE risk of 5-20 per 10,000 woman-years, and the postpartum period carries 40-65 per 10,000 woman-years 8—substantially higher than any COC.

References

Research

SOGC clinical practice guideline. No. 252, December 2010. Oral contraceptives and the risk of venous thromboembolism: an update.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2010

Research

Use of hormones and risk of venous thromboembolism.

Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia, 2024

Guideline

guidelines of care for the management of acne vulgaris.

Journal of the American Academy of Dermatology, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.